Future drug discovery

Keyphrases

Publications

volume 5, number 3, 2023

Vincent Amarh, Benaiah Annertey Abbey, Samuel Akwasi Acheampong, Michael Acheampong Debrah, Gwendolyn Nita Amarquaye, Patrick Kobina Arthur
Codeine dysregulates ribosome biogenesis in Escherichia coli with DNA double-strand breaks to chart path to new classes of antibiotics. Future drug discovery 5 (3) (2023)
Vincent Amarh, Benaiah Annertey Abbey, Samuel Akwasi Acheampong, Michael Acheampong Debrah, Gwendolyn Nita Amarquaye, Patrick Kobina Arthur
Codeine dysregulates ribosome biogenesis in Escherichia coli with DNA double-strand breaks to chart path to new classes of antibiotics. Future drug discovery 5 (3) (2023)

volume 4, number 3, 2023

Marco Cabrera, Meghana Kolli, Meena Jaggi, Subhash C Chauhan, Murali M Yallapu
miRNA-205: a future therapeutic molecule for liver diseases. Future drug discovery 4 (3) (2023)
Marco Cabrera, Meghana Kolli, Meena Jaggi, Subhash C Chauhan, Murali M Yallapu
miRNA-205: a future therapeutic molecule for liver diseases. Future drug discovery 4 (3) (2023)

volume 4, number 4, 2023

Thuy-Tien T Nguyen, William P Katt, Richard A Cerione
Alone and together: current approaches to targeting glutaminase enzymes as part of anti-cancer therapies. Future drug discovery 4 (4) (2023)

volume 4, number 1, 2022

Colin J Suckling, Iain S Hunter, Fraser J Scott
Multitargeted anti-infective drugs: resilience to resistance in the antimicrobial resistance era. Future drug discovery 4 (1) (2022)
Eswara Naga Hanuma Kumar Ghali, Vijian Dhevan, Shravan K Narmala, Meena Jaggi, Subhash C Chauhan, Murali Mohan Yallapu
Breakthrough medicines during the COVID-19 pandemic era. Future drug discovery 4 (1) (2022)
Eswara Naga Hanuma Kumar Ghali, Vijian Dhevan, Shravan K Narmala, Meena Jaggi, Subhash C Chauhan, Murali Mohan Yallapu
Breakthrough medicines during the COVID-19 pandemic era. Future drug discovery 4 (1) (2022)

volume 4, number 2, 2022

Birgit Caspar, Pietro Cocchiara, Armelle Melet, Kristof Van Emelen, Annegret Van der Aa, Graeme Milligan, Jean-Philippe Herbeuval
CXCR4 as a novel target in immunology: moving away from typical antagonists. Future drug discovery 4 (2) (2022)

volume 4, number 1, 2021

Gabrielle Brewer, Anne-Marie N Fortier, Morag Park, Christopher Moraes
The case for cancer-associated fibroblasts: essential elements in cancer drug discovery? Future drug discovery 4 (1) (2021)

volume 2, number 1, 2020

Eric Ni, Eehjoe Kwon, Lauren M Young, Klara Felsovalyi, Jennifer Fuller, Timothy Cardozo
How polypharmacologic is each chemogenomics library? Future drug discovery 2 (1) (2020)

volume 2, number 4, 2020

Vivek K Kashyap, Anupam Dhasmana, Murali M Yallapu, Subhash C Chauhan, Meena Jaggi
Withania somnifera as a potential future drug molecule for COVID-19. Future drug discovery 2 (4) (2020)

volume 1, number 1, 2019

Vidhi Khanna, Stephen Kalscheuer, Ameya Kirtane, Wenqiu Zhang, Jayanth Panyam
Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer. Future drug discovery 1 (1) (2019)

volume 1, number 2, 2019

Lai Wei, Xueliang Pan, Soledad Fernandez
Practical considerations for the implementation of adaptive designs for oncology Phase I dose-finding trials. Future drug discovery 1 (2) (2019)
Tyler C Beck, Thomas A Dix
Targeting peripheral ϰ-opioid receptors for the non-addictive treatment of pain. Future drug discovery 1 (2) (2019)